Aclaris Therapeutics Inc. (ACRS)
Symbol Info
Listed Symbol ACRS
Name Aclaris Therapeutics Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $8,591,000
Latest Fiscal EPS $-4.04
Price Info
21 Day Moving Average $1.3117
21 Day EMA $1.338110
50 Day Moving Average $2.5932
50 Day EMA $2.401820
200 Day EMA $6.498230
200 Day Moving Average 5.991230
52 Week High $16.49
52 Week Low $0.74
52 Week Change $-94.473400
Alpha -0.047659
Beta 0.9027
Standard Deviation 0.190822
R2 0.026243
Periods 46
Share Information
10 Day Average Volume 2,183,407
20 Day Average Volume 1,637,403
30 Day Average Volume 1,262,032
50 Day Average Volume 1,206,265
Outstanding Shares 41,368,224
Float Shares 39,589,342
Percent Float 95.70%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 221
Institute Holdings Date 2019-07-31
Institute Bought Previous 3 Months 3,748,851
Institute Holdings Percent -
Institute Sold Previous 3 Months 5,561,288
Insider Holdings Date
Insider Bought Previous 3 Months -
Insider Holdings Percent -
Insider Sold Previous 3 Months -
Insiders Shares Owned 1,778,882
Price Change
7 Day Price Change $-0.0269
7 Day Percent Change -2.99%
21 Day Price Change $-0.8768
21 Day Percent Change -50.10%
30 Day Price Change $-1.3368001
30 Day Percent Change -60.49%
Month To Date Price Change $-0.4068
Month To Date Percent -31.78%
90 Day Price Change $-4.8868
90 Day Percent Change -84.84%
Quarter To Date $-1.3168
Quarter To Date Percent -60.13%
180 Day Price Change $-6.5468
180 Day Percent Change -88.23%
200 Day Price Change $-5.8568
200 Day Percent Change -87.03%
Year To Date $-6.5168
Year To Date Percent -88.18%
Profile
Description Aclaris Therapeutics Inc is a clinical-stage specialty pharmaceutical company which operates in United States. It focuses on identifying, developing and commercializing differentiated drugs to address significant unmet needs in dermatology. The company holds a drug candidate, A-101 Topical Solution which is a proprietary high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis (SK) a common non-malignant skin tumor. Its pipeline of drug candidates includes A-101 as a Topical Solution for treatment of SK, common warts; A-102 as a gel dosage form for treatment of SK and warts and A-201 and A-301 as an oral and topical formulation for treatment of autoimmune dermatologic respectively.
Details
Issue Type CS
Market Cap $36,122,733
Sec Type EQS
Auditor PricewaterhouseCoopers LLP
Total Shares Outstanding 41,368,224
CEO Neal Walker
Employees 169
Last Audit UQ
Classification
CIK 0001557746
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 640 Lee Road
Suite 200
Wayne, PA 19087
Website http://www.aclaristx.com
Facisimile +1 484 320-2344
Telephone +1 484 324-7933
Email mtung@aclaristx.com
Key Ratios
Profitability
EBIT Margin -870.9
EBITDA Margin -835.1
Pre-Tax Profit Margin -
Profit Margin Cont -
Gross Margin 37.20
Profit Margin TOT -
Income Statements
Revenue $15,703,000
Revenue Per Share $0.3796
Revenue 3 Years $-
Revenue 5 Years $-
Valuation Measures
PE Ratio -
Enterprise Value $-51,519,832
Price To Sales 2.300371
Price To Free Cash -0.2
PE High Last 5 Years -
Price To Book 0.2
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book 0.5
Financial Strength
Total Debt To Equity 0.2
Int Coverage -
Current Ratio 3.2
Leverage Ratio 1.4
Quick Ratio 3.2
Long Term Debt To Capital 0.18
Assets
Receivables Turnover 1.4
Invoice Turnover 16.80
Assets Turnover -
Management Effectiveness
Return Assets -75.76
Return On Equity -101.94
Return On Capital -85.15
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
ACRS
Aclaris Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.